Previous Close | 2.4000 |
Open | 2.3900 |
Bid | 2.3200 x 0 |
Ask | 2.3300 x 0 |
Day's Range | 2.3000 - 2.3900 |
52 Week Range | 2.2550 - 4.8800 |
Volume | |
Avg. Volume | 230,503 |
Market Cap | 891.109M |
Beta (5Y Monthly) | 1.42 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.5600 |
Earnings Date | Aug 07, 2023 - Aug 11, 2023 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 3.45 |
The underwhelming Canadian pot market has made it difficult for these businesses to generate any consistent revenue growth.
Plans to Exit Existing U.S. hemp-derived CBD Operations Intends to Launch Lord Jones® Brand in the Canadian Adult-use Market in Q4 2023 TORONTO, May 31, 2023 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) (“Cronos” or the “Company”), an innovative global cannabinoid company, today announced its decision to streamline its operating structure by winding down and exiting its existing U.S. hemp-derived CBD-focused operations by the end of the second quarter of 2023. Cronos has made
TORONTO, May 30, 2023 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) (“Cronos” or the “Company”), an innovative global cannabinoid company, today announced that Mike Gorenstein, Chairman, President and CEO, will speak at Bernstein's 39th Annual Strategic Decisions Conference on Thursday, June 1, 2023, at 1:30PM ET. A live webcast will be available on the Investors section of the Company’s website at https://ir.thecronosgroup.com/events-presentations. About Cronos Group Inc.Cron
TORONTO, May 12, 2023 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) (“Cronos” or the “Company”), an innovative global cannabinoid company, today announced that Mike Gorenstein, Chairman, President and CEO, will speak at the Canaccord Genuity 7th Annual Global Cannabis Conference on Thursday, May 18, 2023, at 11:00AM ET. A live webcast will be available on the Investors section of the Company’s website at https://ir.thecronosgroup.com/events-presentations. About Cronos Group In
Cronos Group ( TSE:CRON ) First Quarter 2023 Results Key Financial Results Revenue: US$20.1m (down 20% from 1Q 2022...
At this time, I would like to turn the call over to Shayne Laidlaw, investor relations. Thank you, Tanya, and thank you for joining us today to review Cronos' 2023 first quarter financial and business performance. Today, I am joined by our chairman, president, and CEO, Mike Gorenstein; and our CFO, James Holm.
Cronos (CRON) delivered earnings and revenue surprises of 25% and 13.42%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Industry-leading balance sheet with $836 million in cash and short-term investments Targeting positive cash flow in 2024 Net revenue in Canada increased 6% in Q1 2023 compared to Q1 2022; on a constant currency basis net revenue in Canada increased 14% in Q1 2023 compared to Q1 2022 Spinach® was top-10 in retail sales in the flower, edible, vape and pre-roll categories in Q1 2023 TORONTO, May 09, 2023 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) (“Cronos” or the “Company”), t
Oncternal Therapeutics (ONCT) delivered earnings and revenue surprises of 4.76% and 1.50%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
TORONTO, April 28, 2023 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) (“Cronos” or the “Company”) will hold its 2023 Annual Meeting of Shareholders on Thursday, June 22, 2023, at 11:00 a.m. ET. Cronos will be conducting the meeting in a virtual-only format via live audio webcast. Registered shareholders and duly appointed proxyholders will have an equal opportunity to participate in the 2023 Annual Meeting online regardless of their geographic location, including a chance to a
TORONTO, April 25, 2023 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) (“Cronos” or the “Company”) will hold its 2023 first quarter earnings conference call on Tuesday, May 9, 2023 at 8:30 a.m. ET. Cronos’ senior management team will discuss the Company’s financial results and will be available for questions from the investment community after prepared remarks. To attend the conference call or webcast, participants should register online at https://ir.thecronosgroup.com/events-
In honour of Earth Day, released a Sustainability Study, which outlines the benefits of using fermentation ...
TORONTO, April 21, 2023 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) (“Cronos” or the “Company”) today, in honor of Earth Day, released a Sustainability Study, which outlines the benefits of using fermentation manufacturing methods for cannabinoid production over the impact of traditional methods of cannabis extraction, which leverage indoor cultivation methods*. The third-party reviewed results showed that the environmental footprint of growing plants indoors is high and usi
When you see that almost half of the companies in the Pharmaceuticals industry in Canada have price-to-sales ratios (or...
Ethermint enables the use of Ethereum smart contracts within the Cosmo ecosystem and is employed by several chains, including Cronos, Kava, and Canto.
Spinach® rose to 8th place in the pre-roll category, capturing 2.5% market share in Q1 2023, up from 1.4% in Q4 20221 In Q1 2023 Spinach® ranked in the top-10 in all categories it participated in: Flower, Pre-rolls, Vapes and Edibles TORONTO, April 12, 2023 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) (“Cronos”), an innovative global cannabinoid company, is pleased to announce its expanded infused pre-roll offerings under the Spinach® brand. Pre-rolls are one of the fastest-g
Key Insights Cronos Group's significant public companies ownership suggests that the key decisions are influenced by...
The company is trying a new path toward vaping success, but it could be a long time before investors know how well it's really doing.
Cronos (CRON) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
As a result of the quarterly review, S&P Dow Jones Indices will make the following changes in the S&P/TSX Composite Index prior to the open of trading on Monday, March 20, 2023:
These three cryptocurrencies are each plunging as a result of contagion fears, but have intriguing catalysts worth considering.
Thank you, Corey, and thank you for joining us today to review Cronos' 2022 fourth quarter and full year financial and business performance. Today, I am joined by our chairman, president, and CEO, Mike Gorenstein and our CFO, James Holm.
Cronos (CRON) delivered earnings and revenue surprises of -180% and 7.20%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Consolidated net revenue increased 23% in Full Year 2022 compared to Full Year 2021; on a constant currency basis consolidated net revenue increased 28% in Full Year 2022 compared to Full Year 2021 Net revenue in Israel increased 128% in Full Year 2022 compared to Full Year 2021; on a constant currency basis net revenue in Israel increased 137% in Full Year 2022 compared to Full Year 2021 Ended 2022 with $878 million in cash and short-term investments Spinach® became the number one edible brand
Cronos (CRON) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.